Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2004

01-10-2004 | Editorial Commentary

From the magic bullet to an effective therapy: the peptide experience

Author: Luigi Mansi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2004

Login to get access

Excerpt

In this issue, Helisch et al. compare the pretherapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours [1]. This is the last of a series of recently published papers on peptides as valuable targeting agents for tumour diagnosis and therapy [2]. For these purposes peptides have very favourable characteristics: excellent permeability, lack of antigenicity, minimal side-effects and rapid clearance from the body in the presence of high-affinity receptor binding; they are also easy to synthesise and modify chemically, to link to chelators and to radiolabel, creating an optimal system for in vivo diagnosis and therapy using radionuclides. This editorial commentary discusses information deriving from this biological model with a view to addressing the major issues involved in the passage from a wonderful theoretical universe to clinical practice in which the problems of patients with cancer need to be solved. …
Literature
1.
Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, Goke B, et al. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004. DOI 10.1007/s00259-004-1561-6.
2.
Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24(4):389–427.CrossRefPubMed
3.
Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30(10):1338–47.CrossRefPubMed
4.
Reubi JC, Eisenwiener KP, Rink H, Waser B, Macke HR. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002;456(1–3):45–9.CrossRefPubMed
5.
Reubi JC, Korner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging 2004;31:803–10.
6.
Mansi L, Panza N, Battista C, Pacilio G, Salvatore M. The biological approach to radioimmunoscintigraphy. Biomed Pharmacother 1990;44(6):295–301.CrossRefPubMed
7.
Pastore V, Di Lieto E, Mansi L, Rambaldi PF, Santini M, Mancusi R. Intraoperative detection of lung cancer by octreotide labeled to indium-111. Semin Surg Oncol 1998;15:220–2.CrossRefPubMed
8.
Mansi L, Rambaldi PF, Bizzarro A, Panza N, Di Martino S, De Bellis A, Del Vecchio E. Indium-111 octreotide in Graves’ disease and in the evaluation of active exophthalmos. Q J Nucl Med 1995;39:105–10.PubMed
9.
Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30(1):9–15.CrossRefPubMed
10.
Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, Paganelli G. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31(7):1038–46.
11.
Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5(1):42–8.CrossRefPubMed
12.
Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28(12):1751–7.CrossRefPubMed
13.
Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30(4):510–8.PubMed
14.
Lubberink M, Tolmachev V, Widstrom C, Bruskin A, Lundqvist H, Westlin JE. 110mIn-DTPA-d-Phe1-octreotide for imaging of neuroendocrine tumors with PET. J Nucl Med 2002;43(10):1391–7.PubMed
15.
Forrer F, Uusijarvi H, Waldherr C, Cremonesi M, Bernhardt P, Mueller-Brand J, Maecke HR. A comparison of 111In-DOTATOC and 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004. DOI 10.1007/s00259-004-1553-6.
16.
Gabriel M, Decristoforo C, Maina T, Nock B, von Guggenberg E, Cordopatis P, Moncayo R. 99mTc-N4-[Tyr3]octreotate versus 99mTc-EDDA/HYNIC-[Tyr3]octreotide: an intrapatient comparison of two novel technetium-99m labeled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm. 2004;19(1):73–9.CrossRefPubMed
17.
Wester HJ, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau FC, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003;30(1):117–22.CrossRefPubMed
18.
Froidevaux S, Eberle AN, Christe M, Sumanovski L, Heppeler A, Schmitt JS, et al. Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002;98(6):930–7.CrossRefPubMed
19.
de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24(4):368–71.CrossRefPubMed
20.
Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001;28(9):1319–25.CrossRefPubMed
21.
Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273–82.CrossRefPubMed
22.
Erion J, Schmidt T, Wilhelm R, Achilefu S, Srinavasan A. Biodistribution and radiotherapy studies using samarium-153 and lutetium-177 DTPA conjugates of Y3-Octreotate. J Nucl Med 1999;40 (Suppl):223P.
23.
De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med. 2002;32(2):133–40.CrossRefPubMed
24.
de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA0,Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;92(5):628–33.CrossRefPubMed
25.
Valdes Olmos RA, Hoefnagel CA. Radionuclide therapy in oncology: the dawning of its concomitant use with other modalities? Eur J Nucl Med Mol Imaging 2004;31(7):929–31.
26.
Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30(2):207–16.PubMed
27.
Chung JK, Kang JH. Translational research using the sodium/iodide symporter in imaging and therapy. J Nucl Med Mol Imaging 2004;31:799–802.
Metadata
Title
From the magic bullet to an effective therapy: the peptide experience
Author
Luigi Mansi
Publication date
01-10-2004
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2004
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-004-1661-3

Other articles of this Issue 10/2004

European Journal of Nuclear Medicine and Molecular Imaging 10/2004 Go to the issue

Original Articles

Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma

EditorialNotes

The growing importance of continuing medical education in nuclear medicine: the role of the European School of Nuclear Medicine

Original Article

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

Review Article

Management of thyroid nodules: a clinicopathological, evidence-based approach

Original Article

Use of 99mTc-sestamibi gated SPECT to assess the influence of anterograde flow before primary coronary angioplasty on tissue salvage and functional recovery in acute myocardial infarction

Erratum

Monte Carlo-based down-scatter correction of SPECT attenuation maps